Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Gain expert insights on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for IBD and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic.

Marla Dubinsky, MD

Bruce E. Sands, MD, MS

On-Demand Webcast

Multimedia

Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

View Multimedia

In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.

Marla Dubinsky, MD

Bruce E. Sands, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: February 16, 2022 Expired: February 15, 2023

Introduction and Presurvey

Why TDM for the Management of IBD?

Reactive vs Proactive TDM With Anti-TNFs

Early Induction and Dosing Calculators

Reactive and Proactive TDM With Non-TNFs